Vertex hits $3.33 billion as revenue growth accelerates
Share
- Vertex reported Q2 revenue of $3.33 billion, up 12%, with GAAP net income reaching $1.1 billion.
- Vertex shares closed regular trading down 1.26% at $471.09 before the after-hours earnings reaction developed.
- Vertex raised its 2026 revenue guidance to $13.1–$13.2 billion, supported by CF treatments and newer products.
Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 revenue of $3.33 billion, up 12%, as its CF and newer treatments generated growth.
Revenue exceeded the prior year’s $2.96 billion, while GAAP net income increased to $1.1 billion from $1 billion.
Vertex raised 2026 revenue guidance to $13.1–$13.2 billion while maintaining non-GAAP combined expense guidance of $5.65–$5.75 billion.
CASGEVY revenue rose 151% to $76.4 million, while JOURNAVX revenue more than quadrupled to $49.6 million.
Vertex held $13.6 billion in cash and investments and expects its $10 billion Crinetics acquisition to close during Q3 2026.
